Trends in dermatologic biologic prescribing: A Medicare Part D Public Use File analysis from 2018 to 2023 - 18/12/25
Doi : 10.1016/j.jaad.2025.09.041
Cathleen V. D'Angelo, BS a, ⁎ 
, Patricia Wilberger, BS b, Chase Merritt, BA a, Joshua Burshtein, MD c, Dawn Merritt, DO d, e
, Patricia Wilberger, BS b, Chase Merritt, BA a, Joshua Burshtein, MD c, Dawn Merritt, DO d, e a Ohio University Heritage College of Osteopathic Medicine, Dublin, Ohio
b Ohio University Heritage College of Osteopathic Medicine, Athens, Ohio
c Department of Dermatology, University of Illinois-Chicago, Chicago, Illinois
d Oakview Dermatology, Athens, Ohio
e Department of Dermatology, OhioHealth Riverside Methodist Hospital, Columbus, Ohio
∗ Correspondence to: Cathleen V. D'Angelo, BS, Ohio University Heritage College of Osteopathic Medicine, 6775 Bobcat Way, Dublin, OH 43016 Ohio University Heritage College of Osteopathic Medicine 6775 Bobcat Way Dublin OH 43016
Key words : biologics, Medicare Part D, prescribing trends
| Funding sources: None. |
|
| Patient consent: Not applicable. |
|
| IRB approval status: Not applicable. |
© 2025
The Author(s). Publié par Elsevier Masson SAS. Tous droits réservés.
Vol 94 - N° 1
P. 335-337 - janvier 2026 Retour au numéro
Article précédent
- Rural-urban differences in management and survival of sebaceous carcinoma: A National Cancer Database analysis
- Rachel C. Chang, Elise K. Brunsgaard, David C. Reid
- The Standard Dermatology Outcome Measures questionnaire captures improvements in dermatologic disease burden
- Ania Stolarczyk, Alice Pentland, Clayton Green, Suephy C. Chen, Julie Ryan Wolf
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?